JNJ-78306358

N/A

Report date: 2026/03/19 17:22:32

Base Information

Drug NameJNJ-78306358

Drug Alias NameJNJ-78306358JNJ-6358

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD8-positive T-Lymphocytes stimulantsHLA class I histocompatibility antigen, alpha chain G inhibitors

TargetsT cell surface glycoprotein CD3Human leukocyte antigenHLA class I histocompatibility antigen, alpha chain G

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsraelSpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJanssen Research & Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A